Rosalind M Glasspool

14PUBLICATIONS
164CO-AUTHORS
Haematological tumoursPhylogeny and comparative analysisCancer therapy (excl. chemotherapy and radiation therapy)Solid tumoursPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|May 02, 2026
Hedgehog Inhibitor and Paclitaxel: A Phase I Trial of the Oral Hedgehog inhibitor Taladegib in Combination with Weekly Paclitaxel in Patients with Advanced Solid Tumours.

|Jul 02, 2025
Divergent trajectories to structural diversity impact patient survival in high grade serous ovarian cancer.

Ailith Ewing, Alison Meynert, Ryan Silk

|Mar 18, 2025
Overall survival with maintenance olaparib in platinum-sensitive relapsed ovarian cancer by somatic or germline BRCA and homologous recombination repair mutation status.

Sandro Pignata, Amit Oza, Geoff Hall

|Jan 20, 2024
Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer.

Shibani Nicum, Naomi McGregor, Rachel Austin

|Dec 09, 2022
Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10.

Rebecca S Kristeleit, Yvette Drew, Amit M Oza

|Oct 07, 2022
Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin.

Gwo Yaw Ho, Elizabeth L Kyran, Justin Bedo

Pageof 3

Frequent Collaborators

8 joint publications

Iain McNeish

4 joint publications

Anna deFazio

3 joint publications

Suzanne Dowson

3 joint publications

James D Brenton